Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab

15 October 2024

South Korea-based biosimilar drug developer Celltrion (Kosdaq: 068270) today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in Vienna, Austria.

The post-hoc analysis from the LIBERTY-CD (Crohn’s disease) and LIBERTY-UC (ulcerative colitis) studies suggest that dose escalation of CT-P13 SC following intravenous (IV) induction in patients who initially respond but subsequently lose response, showed clinical efficacy over an extended period of 102 weeks.

In the study, patients showed improvement in clinical remission at Week 102 [70.3% (26/37) in CD and 35.2% (25/71) in UC] or endoscopic response [40.5% (15/37) in CD] after dose escalation. Compared to the first dose escalation visit, patients who escalated the dose had a statistically significant reduction in mean modified Mayo score in UC (5.9 vs 2.1, P<0.0001) and mean CDAI score in CD (270.58 vs 76.31, P<0.0001) at Week 102.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK